← Search

American Economic Review Vol. 96 No. 2 2006

Did Medicare Induce Pharmaceutical Innovation?

Daron Acemoglu1; David Cutler2; Amy Finkelstein3; Joshua Linn4

1 Department of Economics, MIT and NBER, Massachusetts Institute of Technology, 50 Memorial Drive, Cambridge, MA 02142. · 2 Department of Economics, Harvard University and NBER, Littauer Center, 1875 Cambridge Street, Cambridge, MA 02138. · 3 Department of Economics, Massachusetts Institute of Technology and NBER, 1050 Massachusetts Avenue, Cambridge, MA 02138. · 4 Department of Economics, University of Illinois at Chicago, 601 South Morgan, Chicago, IL 60607.

Abstract

The introduction of Medicare in 1965 was the single largest change in health insurance coverage in U.S. history.Many economists and commentators have conjectured that the introduction of Medicare may have also been an important impetus for the development of new drugs that are now commonly used by the elderly and have substantially extended their life expectancy.In this paper, we investigate whether Medicare induced pharmaceutical innovations directed towards the elderly.Medicare could have played such a role only if two conditions were met.First, Medicare would have to increase drug spending by the elderly.Second, the pharmaceutical companies would have to respond to the change in market size for drugs caused by Medicare by changing the direction of their research.Our empirical work finds no evidence of a "first-stage" effect of Medicare on prescription drug expenditure by the elderly.Correspondingly, we also find no evidence of a shift in pharmaceutical innovation towards therapeutic categories most used by the elderly.On the whole, therefore, our evidence does not provide support for the hypothesis that Medicare had a major effect on the direction of pharmaceutical innovation.

DOI
10.1257/000282806777211766
Volume
96
Issue
2
Pages
103-107
Language
en
Sources
bibtex:phds-export.bib crossref openalex

Cite